肝移植后免疫抑制的不良反应。
Adverse effects of immunosuppression after liver transplantation.
机构信息
Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.
Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France; Grenoble Alpes University, Grenoble, France.
出版信息
Best Pract Res Clin Gastroenterol. 2021 Oct-Dec;54-55:101762. doi: 10.1016/j.bpg.2021.101762. Epub 2021 Sep 2.
After solid organ transplantation the cornerstone of immunosuppression is based on calcineurin inhibitors (CNIs), mostly tacrolimus. However, CNIs have a very narrow therapeutic window. The most important and serious side-effects of CNIs are nephrotoxicity, high blood pressure, post-transplant diabetes mellitus (PTMD), i.e., new-onset diabetes after transplantation (NODAT), dyslipidemia, and modification to the cardiovascular-risk profile. In this review, we will focus on tacrolimus-related toxicities in the setting of liver transplantation.
在实体器官移植后，免疫抑制的基石基于钙调磷酸酶抑制剂（CNIs），主要是他克莫司。然而，CNIs 的治疗窗非常窄。CNIs 最重要和最严重的副作用是肾毒性、高血压、移植后糖尿病（PTMD），即移植后新发糖尿病（NODAT）、血脂异常以及心血管风险谱的改变。在这篇综述中，我们将重点讨论肝移植中与他克莫司相关的毒性。
Zotero 插件